Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Mayo Pujols is currently VP Global Head Car-T Operations and Technology at Celgene..." Not sure if this was already posted.
Chris Duke is COO. I would think that's a key position.
Anyone called IR to ask about the management leaving?
So, again, would there not be a filing to report them leaving?
Would the leaving of senior management have to be reported?
This was tweeted by Advaxis. Possibly why it was chosen as a target for NEO.
http://www.targetedonc.com/news/will-combination-therapies-with-immunotherapy-become-the-new-standard-of-care-for-nsclc
I rather thought there might be.
What I find truly disappointing is, given the stellar canine results, nobody has (as far as I know) come forward to sponsor a trial which could make children's suffering so much less.
Let's see what happens Tuesday when the short numbers are updated Monday PM.
And it was kept in a tight range until 3:45P. Looking at the Yahoo chart, the biggest spikes all day were green.
ASCO (June 1-5) unless a PR comes out before.
And it's an interim position. If the person knows they're in an interim position how can they be involuntarily terminated?
If those companies do nothing with the license, can it be revoked?
From Bourbon's post regarding NEO, "Lots of progress being made, some of which AMGN wants to keep quiet for competitive reasons." That sounds rather promising. NEO is recruiting, now they need to find suitable candidates.If the prostate combo data is really good, I expect we'll see quite a bit of interest from Merck. A new CEO is slated to take over mid-year. Hopefully, he or she will have name recognition to bolster confidence. So, there is a reason for (cautious) optimism.
That is what I am hoping.
For second-line conditional approval, I'm not sure what the revenue would be but just having the approval would be further validation of AXAL. It could possibly cause other companies that licensed the product to file in their own areas.
And what has any one of those companies done to move these to market? I know Biocon applied for approval in India but was shot down. Apparently their approving agency wanted more data (PIII). I sent an email to Biocon asking if they would consider refiling as AIM2CERV was running but never heard back.
New CEO supposed to be in place by midyear.
"Looking to the future, we anticipate that strategic management team appointments for both the CEO and CMO positions will be finalized by mid-2018."
Bourbon, this is an excellent suggestion. Did you have a chance to talk with management after the meeting?
AXAL has orphan status, if that's what management was referring to.
Was anything mentioned regarding prostate cancer?
Bourbon, thanks for the updates. I think NEO will be a big value driver. Your efforts are very much appreciated.
Now, add Axalimogene Filolisbac and they should have a winner!
https://immuno-oncologynews.com/2018/03/16/mercks-keytruda-fda-priority-review-cervical-cancer/?utm_source=IO+News&utm_campaign=daf2157c8e-RSS_WEEKLY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_f04c303b86-daf2157c8e-72345901
ADRO is certainly bucking the trend today.
"Werewolf!" "There wolf, there castle."
"Put the candle back!"
Considering the limited distribution at the moment, you are probably in the ballpark.
Some companies unbelievably higher or equal to ADXS, as of Friday. CLSN = $2.58, CYTR = $2.11, HTBX = $2.05, INO = $5.15, TPIV = $3.65. Can we get a little love here?
They're probably getting (or will get) a bit from Aratana. Has anyone ever found out what else was licensed by Aratana?
You got your wish, though someone was trying to bring it down at the end.
By whom?
If the new CEO wants to pick the CMO, I could see that happening. You are right, though, it's unusual.
I'll take what's behind door number 1.
Since the company is running Aim2Cerv as the PIII, wouldn't that serve as the confirmation trial for conditional approval? There are few options for recurrent cervical cancer. I would hope the EMA keeps this first and foremost in their minds.
When (not if) there is full approval the revenue may increase but I do remember DOC saying the revenue was not much. I don't think it was a very good deal though Aratana also got three (?) other constructs but no one seems to know what they are. I emailed Aratana some time ago about the others but received no reply.
Exactly, so how much would the revenue be until then?
Never said it was trivial. I said it was minimal. I think DOC even said it would not be much.
Big money from the osteosarcoma vaccine? It's been given a conditional approval and will only be sold, for the time being, at a few selected vet's offices. Revenue will be minimal at best.
I still think a new CEO will be announced soon, maybe not Monday but there was certainly a lot of movement late Friday so maybe something else in the works. Should you buy back? Well, of course that's a personal choice but if you feel it could be upward momentum from here then you could always get a small stake.
New job posting:
Manager/Senior Manager, Quality Assurance
Job Locations US-Princeton
Posted Date 21 hours ago(3/9/2018 12:09 PM)
ID 2018-1120
Overview
Manages the supplier qualification program to include external audit program, maintenance of Approved Supplier List, supplier metrics and relationships. Work within the realms of GMP systems to facilitate batch release, change control, and deviation, particularly as they relate to vendor management. Support on-site clinical manufacturing activities to support all incoming component and material release ensuring complaint, robust and consistent manufacturing, testing and clinical development processes are established and maintained.